BridgeBio Pharma Inc (BBIO)’s financial ratios: A comprehensive overview

BridgeBio Pharma Inc (NASDAQ: BBIO) closed the day trading at $30.86 up 3.70% from the previous closing price of $29.76. In other words, the price has increased by $+1.10 from its previous closing price. On the day, 1784867 shares were traded.

Ratios:

For a better understanding of BBIO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.32 and its Current Ratio is at 3.32.

On January 31, 2024, BMO Capital Markets started tracking the stock assigning a Market Perform rating and target price of $37.

On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $58.Wells Fargo initiated its Overweight rating on December 08, 2023, with a $58 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 01 ’24 when Scott Randal W. sold 2,500 shares for $34.00 per share. The transaction valued at 85,000 led to the insider holds 6,500 shares of the business.

Valantine Hannah sold 2,915 shares of BBIO for $110,041 on Feb 15 ’24. The Director now owns 1,764 shares after completing the transaction at $37.75 per share. On Jan 16 ’24, another insider, Valantine Hannah, who serves as the Director of the company, sold 2,915 shares for $37.97 each. As a result, the insider received 110,683 and left with 1,764 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBIO now has a Market Capitalization of 5.70B and an Enterprise Value of 7.00B. For the stock, the TTM Price-to-Sale (P/S) ratio is 612.06. Its current Enterprise Value per Revenue stands at 752.54 whereas that against EBITDA is -12.38.

Stock Price History:

Over the past 52 weeks, BBIO has reached a high of $44.32, while it has fallen to a 52-week low of $12.75. The 50-Day Moving Average of the stock is 33.14, while the 200-Day Moving Average is calculated to be 29.76.

Shares Statistics:

Over the past 3-months, BBIO traded about 1.81M shares per day on average, while over the past 10 days, BBIO traded about 1.68M shares per day. A total of 175.08M shares are outstanding, with a floating share count of 136.57M. Insiders hold about 25.96% of the company’s shares, while institutions hold 71.52% stake in the company. Shares short for BBIO as of Feb 29, 2024 were 13.64M with a Short Ratio of 7.39, compared to 14.21M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.76% and a Short% of Float of 12.57%.

Earnings Estimates

Current recommendations for the stock of the company come from 9 analysts. On average, analysts expect EPS of -$0.92 for the current quarter, with a high estimate of -$0.74 and a low estimate of -$1.18, while EPS last year was -$0.92. The consensus estimate for the next quarter is -$0.94, with high estimates of -$0.77 and low estimates of -$1.27.

Analysts are recommending an EPS of between -$1.58 and -$5.03 for the fiscal current year, implying an average EPS of -$3.25. EPS for the following year is -$3.03, with 11 analysts recommending between -$1.84 and -$4.85.

Revenue Estimates

A total of 7 analysts have provided revenue estimates for BBIO’s current fiscal year. The highest revenue estimate was $459.78M, while the lowest revenue estimate was $12.9M, resulting in an average revenue estimate of $169.28M. In the same quarter a year ago, actual revenue was $9.3M, up 1,719.60% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $193M in the next fiscal year. The high estimate is $256.97M and the low estimate is $116.1M. The average revenue growth estimate for next year is up 14.00% from the average revenue estimate for this year.

Most Popular